exhibit 10. 7 certain confidential information contained in this document, marked by [ * * * ], has been omitted because it is both ( i ) not material and ( ii ) would be competitively harmful if publicly disclosed. technology license agreement parties this technology license agreement ( the “ agreement ” ) is entered into by and between lantern pharma inc., a texas corporation ( hereinafter referred to as “ lantern ” ) having principal offices at 211, n ervay st, dallas, tx 75201 and af chemicals, llc, a californian limited liability company having principal offices at 5545 coral reef, la jolla, ca 92037 ( hereinafter referred to as “ afc ” ) each individually referred to hereinafter as a “ party ” and collectively referred to hereinafter as the “ parties ”. recitals whereas, lantern has expertise in drug development and partnering with biotechnology / biopharmaceutical / pharmaceutical companies in funding, gaining regulatory approval, manufacturing, marketing and distribution of the targeted compounds ; whereas afc has rights to the targeted compounds ; whereas, lantern desires to acquire right, title and interest in and to the licensed technology in the field of use. now, therefore, for good and valuable consideration the parties, intending to be legally bound hereby, agree that they shall be subject to the following terms and conditions : terms of agreement 1. definitions 1. 1 “ targeted compounds ” shall mean any illudin, acylfulvene or irofulven analog composition in one or more patents listed in exhibit a, ( ii ) or otherwise belonging to a genus that is covered by one or more claims of the one or more patents listed in exhibit a, ( iii ) together with rights in technical information recorded in the form of drawings, plans, specification, diagrams, trade secrets as defined by the uniform trade secrets act and other data relating to the manufacture, design and improvement of the targeted compounds and ( iv ) any afc inventions together with ( v ) any improvements of the targeted compounds as they now exist or may become available throughout the life of the agreement irrespective of whether such improvements are necessary to manufacture the targeted compounds, but excluding the targeted compounds when bound or conjugated to any moiety including for example an illudin, illudin analog, acylfulvene analog, irofulven or irofulven analog bound either directly or via a linker to